Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Prostate cancer is a life-altering diagnosis, not just for patients, but for their loved ones as well. Once, prostate cancer was most frequently diagnosed in men in their 60s and 70s; with increasing use of imaging modalities and PSA testing, the incidence is on the rise, and we are now seeing men in their 40s with the disease. This poses a challenge for clinical management depending on the stage of the disease—from watchful waiting or active surveillance to aggressive treatment with the risk of therapeutic nihilism. Despite being one of the most common cancers in Western men, its natural history, prognosis, and treatment are poorly understood. This book brings together a select faculty of experts to present a comprehensive view of the current state and future perspectives of prostate cancer. There are ten chapters in the book—the first four cover our present knowledge and understanding of the disease, the following three explore new advancements and treatments, particularly looking at overcoming resistance to therapy, and the remaining three chapters focus on specific molecules with the potential to become drug targets. We all have much to learn about prostate cancer. This book is aimed primarily at clinicians and scientists, but many areas will also be of interest to the layperson.

Prostate --- Epidemiology of Prostate Cancer; Etiology of Prostate Cancer; Pathogenesis of Prostate Cancer; Current Diagnostics for Prostate Cancer; Combination Treatment for Prostate Cancer; Castration-Resistant Prostate Cancer; Theranostics in Metastatic Castrate Resistant Prostate Cancer; Adenocarcinoma of the Prostate; p53 in Prostate Cancer; MUCIN 1 in Prostate Cancer; STEAP Proteins in Prostate Cancer --- Cancer. --- Epidemiology of Prostate Cancer; Etiology of Prostate Cancer; Pathogenesis of Prostate Cancer; Current Diagnostics for Prostate Cancer; Combination Treatment for Prostate Cancer; Castration-Resistant Prostate Cancer; Theranostics in Metastatic Castrate Resistant Prostate Cancer; Adenocarcinoma of the Prostate; p53 in Prostate Cancer; MUCIN 1 in Prostate Cancer; STEAP Proteins in Prostate Cancer

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Prostate cancer is a life-altering diagnosis, not just for patients, but for their loved ones as well. Once, prostate cancer was most frequently diagnosed in men in their 60s and 70s; with increasing use of imaging modalities and PSA testing, the incidence is on the rise, and we are now seeing men in their 40s with the disease. This poses a challenge for clinical management depending on the stage of the disease—from watchful waiting or active surveillance to aggressive treatment with the risk of therapeutic nihilism. Despite being one of the most common cancers in Western men, its natural history, prognosis, and treatment are poorly understood. This book brings together a select faculty of experts to present a comprehensive view of the current state and future perspectives of prostate cancer. There are ten chapters in the book—the first four cover our present knowledge and understanding of the disease, the following three explore new advancements and treatments, particularly looking at overcoming resistance to therapy, and the remaining three chapters focus on specific molecules with the potential to become drug targets. We all have much to learn about prostate cancer. This book is aimed primarily at clinicians and scientists, but many areas will also be of interest to the layperson.

Prostate --- Cancer. --- Epidemiology of Prostate Cancer; Etiology of Prostate Cancer; Pathogenesis of Prostate Cancer; Current Diagnostics for Prostate Cancer; Combination Treatment for Prostate Cancer; Castration-Resistant Prostate Cancer; Theranostics in Metastatic Castrate Resistant Prostate Cancer; Adenocarcinoma of the Prostate; p53 in Prostate Cancer; MUCIN 1 in Prostate Cancer; STEAP Proteins in Prostate Cancer

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

The issue of Cancers Journal entitled “Role of Medical Imaging in Cancers” presents a detailed summary of evidences about molecular imaging, including the role of computed tomography (CT), magnetic resonance imaging (MRI), single photon emission tomography (SPET) and positron emission tomography (PET) or PET/CT or PET/MR imaging in many type of tumors (i.e. sarcoma, prostate, breast and others), motivating the role of these imaging modalities in different setting of disease and showing the recent developments, in terms of radiopharmaceuticals, software and artificial intelligence in this field. The collection of articles is very useful for many specialists, because it has been conceived for a multidisciplinary point of view, in order to drive to a personalized medicine.

Medicine. --- positron emission tomography --- head and neck neoplasms --- neovascularization --- pathologic --- PET/CT --- urothelial carcinoma --- bladder cancer --- upper tract urothelial carcinoma --- survival --- PET --- PSMA --- prostate --- DCFPyL --- DCFBC --- PSMA-1007 --- ovarian cancer --- relapse --- SUVmax --- targeted therapy --- prognosis --- soft tissue sarcoma (STS) --- pazopanib --- dynamic 18F-FDG PET/CT --- SUV --- two-tissue compartment model --- magnetic resonance imaging --- machine learning --- diffusion --- perfusion --- texture analysis --- squamous cell carcinoma of the head and neck --- diffusion-weighted imaging --- malignant pleural mesothelioma --- pleural dissemination --- empyema --- pleural effusion --- mCRPC --- SPECT/CT --- Computer-assisted diagnosis --- XOFIGO --- Therapy response assessment --- circulating miRNAs --- breast cancer --- imaging parameters --- PET/MRI --- biomarkers --- triple negative breast cancer --- VCAM-1 --- SPECT imaging --- sdAbs --- Hounsfield unit --- computed tomography --- adipose tissue --- precision oncology --- FDG-PET/CT --- PERCIST --- metastatic breast cancer --- prostate cancer --- 18F-FACBC --- recurrence --- meta-analysis --- review --- meningioma --- somatostatin receptor --- neuroimaging --- radionuclide therapy --- breast --- imaging --- marker --- radiomics --- Yin Yang 1 --- PDAC --- Mesothelin --- noninvasive imaging --- receptor status --- molecular imaging --- nuclear medicine --- guidelines --- overutilization --- epistemology --- consensus --- mantle cell lymphoma --- 18F-FDG PET/CT --- Deauville criteria --- Radium-223 --- FDG --- castrate resistant prostate cancer --- programmed cell death 1 receptor --- diagnostic imaging --- CTLA-4 Antigen --- Immunotherapy --- Adoptive --- radioactive tracers --- radionuclide imaging --- CD8-Positive T-Lymphocytes --- PI-RADS --- diffusion kurtosis imaging --- dynamic contrast-enhanced magnetic resonance imaging --- 68Gallium-PSMA PET/CT --- prostate-specific-antigen --- PSA kinetics thresholds --- biochemical recurrence --- optimal cutoff level --- non-small-cell lung cancer --- circulating tumor cells --- immunotherapy --- response to treatment --- head and neck cancer --- HPV --- EBV --- p16 --- Molecular imaging --- miRNA expression --- radiogenomics --- radiomic --- diagnosis --- biomarker --- glioblastoma --- radiation therapy --- MRI --- diffusion tensor imaging --- Hodgkin lymphoma --- diffuse large B-cell lymphoma --- staging --- response assessment --- locally advanced cervical cancer --- concurrent chemoradiotherapy --- treatment response --- follow up --- cystic tumor --- International Consensus Guidelines --- intraductal papillary mucinous neoplasms --- pancreatic neoplasms --- PD-1 --- PD-L1 --- response to therapy --- NSCLC --- positron-emission tomography --- single-photon emission computed tomography --- immune checkpoint inhibitors --- gold nanoparticle --- heat shock protein 70 --- spectral-CT --- positron emission tomography --- head and neck neoplasms --- neovascularization --- pathologic --- PET/CT --- urothelial carcinoma --- bladder cancer --- upper tract urothelial carcinoma --- survival --- PET --- PSMA --- prostate --- DCFPyL --- DCFBC --- PSMA-1007 --- ovarian cancer --- relapse --- SUVmax --- targeted therapy --- prognosis --- soft tissue sarcoma (STS) --- pazopanib --- dynamic 18F-FDG PET/CT --- SUV --- two-tissue compartment model --- magnetic resonance imaging --- machine learning --- diffusion --- perfusion --- texture analysis --- squamous cell carcinoma of the head and neck --- diffusion-weighted imaging --- malignant pleural mesothelioma --- pleural dissemination --- empyema --- pleural effusion --- mCRPC --- SPECT/CT --- Computer-assisted diagnosis --- XOFIGO --- Therapy response assessment --- circulating miRNAs --- breast cancer --- imaging parameters --- PET/MRI --- biomarkers --- triple negative breast cancer --- VCAM-1 --- SPECT imaging --- sdAbs --- Hounsfield unit --- computed tomography --- adipose tissue --- precision oncology --- FDG-PET/CT --- PERCIST --- metastatic breast cancer --- prostate cancer --- 18F-FACBC --- recurrence --- meta-analysis --- review --- meningioma --- somatostatin receptor --- neuroimaging --- radionuclide therapy --- breast --- imaging --- marker --- radiomics --- Yin Yang 1 --- PDAC --- Mesothelin --- noninvasive imaging --- receptor status --- molecular imaging --- nuclear medicine --- guidelines --- overutilization --- epistemology --- consensus --- mantle cell lymphoma --- 18F-FDG PET/CT --- Deauville criteria --- Radium-223 --- FDG --- castrate resistant prostate cancer --- programmed cell death 1 receptor --- diagnostic imaging --- CTLA-4 Antigen --- Immunotherapy --- Adoptive --- radioactive tracers --- radionuclide imaging --- CD8-Positive T-Lymphocytes --- PI-RADS --- diffusion kurtosis imaging --- dynamic contrast-enhanced magnetic resonance imaging --- 68Gallium-PSMA PET/CT --- prostate-specific-antigen --- PSA kinetics thresholds --- biochemical recurrence --- optimal cutoff level --- non-small-cell lung cancer --- circulating tumor cells --- immunotherapy --- response to treatment --- head and neck cancer --- HPV --- EBV --- p16 --- Molecular imaging --- miRNA expression --- radiogenomics --- radiomic --- diagnosis --- biomarker --- glioblastoma --- radiation therapy --- MRI --- diffusion tensor imaging --- Hodgkin lymphoma --- diffuse large B-cell lymphoma --- staging --- response assessment --- locally advanced cervical cancer --- concurrent chemoradiotherapy --- treatment response --- follow up --- cystic tumor --- International Consensus Guidelines --- intraductal papillary mucinous neoplasms --- pancreatic neoplasms --- PD-1 --- PD-L1 --- response to therapy --- NSCLC --- positron-emission tomography --- single-photon emission computed tomography --- immune checkpoint inhibitors --- gold nanoparticle --- heat shock protein 70 --- spectral-CT

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

undefined

Medicine. --- positron emission tomography --- head and neck neoplasms --- neovascularization --- pathologic --- PET/CT --- urothelial carcinoma --- bladder cancer --- upper tract urothelial carcinoma --- survival --- PET --- PSMA --- prostate --- DCFPyL --- DCFBC --- PSMA-1007 --- ovarian cancer --- relapse --- SUVmax --- targeted therapy --- prognosis --- soft tissue sarcoma (STS) --- pazopanib --- dynamic 18F-FDG PET/CT --- SUV --- two-tissue compartment model --- magnetic resonance imaging --- machine learning --- diffusion --- perfusion --- texture analysis --- squamous cell carcinoma of the head and neck --- diffusion-weighted imaging --- malignant pleural mesothelioma --- pleural dissemination --- empyema --- pleural effusion --- mCRPC --- SPECT/CT --- Computer-assisted diagnosis --- XOFIGO --- Therapy response assessment --- circulating miRNAs --- breast cancer --- imaging parameters --- PET/MRI --- biomarkers --- triple negative breast cancer --- VCAM-1 --- SPECT imaging --- sdAbs --- Hounsfield unit --- computed tomography --- adipose tissue --- precision oncology --- FDG-PET/CT --- PERCIST --- metastatic breast cancer --- prostate cancer --- 18F-FACBC --- recurrence --- meta-analysis --- review --- meningioma --- somatostatin receptor --- neuroimaging --- radionuclide therapy --- breast --- imaging --- marker --- radiomics --- Yin Yang 1 --- PDAC --- Mesothelin --- noninvasive imaging --- receptor status --- molecular imaging --- nuclear medicine --- guidelines --- overutilization --- epistemology --- consensus --- mantle cell lymphoma --- 18F-FDG PET/CT --- Deauville criteria --- Radium-223 --- FDG --- castrate resistant prostate cancer --- programmed cell death 1 receptor --- diagnostic imaging --- CTLA-4 Antigen --- Immunotherapy --- Adoptive --- radioactive tracers --- radionuclide imaging --- CD8-Positive T-Lymphocytes --- PI-RADS --- diffusion kurtosis imaging --- dynamic contrast-enhanced magnetic resonance imaging --- 68Gallium-PSMA PET/CT --- prostate-specific-antigen --- PSA kinetics thresholds --- biochemical recurrence --- optimal cutoff level --- non-small-cell lung cancer --- circulating tumor cells --- immunotherapy --- response to treatment --- head and neck cancer --- HPV --- EBV --- p16 --- Molecular imaging --- miRNA expression --- radiogenomics --- radiomic --- diagnosis --- biomarker --- glioblastoma --- radiation therapy --- MRI --- diffusion tensor imaging --- Hodgkin lymphoma --- diffuse large B-cell lymphoma --- staging --- response assessment --- locally advanced cervical cancer --- concurrent chemoradiotherapy --- treatment response --- follow up --- cystic tumor --- International Consensus Guidelines --- intraductal papillary mucinous neoplasms --- pancreatic neoplasms --- PD-1 --- PD-L1 --- response to therapy --- NSCLC --- positron-emission tomography --- single-photon emission computed tomography --- immune checkpoint inhibitors --- gold nanoparticle --- heat shock protein 70 --- spectral-CT --- n/a